14-May-2024
Synlogic GAAP EPS of -$2.60 misses by $1.80
Seeking Alpha News (Tue, 14-May 7:20 AM ET)
Synlogic Reports First Quarter 2024 Financial Results
Globe Newswire (Tue, 14-May 7:00 AM ET)
Business Wire (Mon, 1-Apr 8:00 AM ET)
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Tue, 19-Mar 7:00 AM ET)
Synlogic Adopts Limited Duration Stockholders Rights Plan
Globe Newswire (Tue, 20-Feb 12:15 PM ET)
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Synlogic trades on the NASDAQ stock market under the symbol SYBX.
As of May 14, 2024, SYBX stock price declined to $1.75 with 19,080 million shares trading.
SYBX has a beta of 0.67, meaning it tends to be less sensitive to market movements. SYBX has a correlation of 0.01 to the broad based SPY ETF.
SYBX has a market cap of $20.38 million. This is considered a Sub-Micro Cap stock.
Last quarter Synlogic reported $3 million in Revenue and -$1.71 earnings per share. This beat revenue expectation by $39,000 and missed earnings estimates by -$.74.
In the last 3 years, SYBX stock traded as high as $68.10 and as low as $1.55.
The top ETF exchange traded funds that SYBX belongs to (by Net Assets): VTI, VXF.
SYBX has underperformed the market in the last year with a price return of -79.0% while the SPY ETF gained +28.8%. SYBX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +0.6% and -6.4%, respectively, while the SPY returned +6.2% and +2.6%, respectively.
SYBX support price is $1.73 and resistance is $1.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYBX stock will trade within this expected range on the day.